@article{JGO33,
author = {Adam Kotowski and Wen Ma},
title = {Emerging therapies in pancreas cancer},
journal = {Journal of Gastrointestinal Oncology},
volume = {2},
number = {2},
year = {2011},
keywords = {},
abstract = {Pancreas cancer has a grave prognosis and treatment options remain limited despite advancement in anti-cancer chemotherapeutics. This review provides an overview of the emerging therapies for pancreas cancer, focusing on novel signal transduction inhibitors (insulin-like growth factor receptor, hedgehog/Smo, PI3k/Akt/mTOR) and cytotoxics (nabpaclitaxel) that are currently in clinical development. Despite the impact molecularly targeted agents have on other tumor types, their application without cytotoxics in pancreas cancer remains limited. In addition, recent report of the superiority of an intensive cytotoxic regimen using fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) over gemcitabine reminded us of the importance of cytotoxics in this disease. As such, the future of pancreas cancer therapy may be combination regimens consisting of cytotoxics and molecularly targeted agents.},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/33}
}